000060659 001__ 60659
000060659 005__ 20210303162448.0
000060659 0247_ $$2doi$$a10.3390/ijms18010197
000060659 0248_ $$2sideral$$a98053
000060659 037__ $$aART-2017-98053
000060659 041__ $$aeng
000060659 100__ $$aMármol Peguero, Inés
000060659 245__ $$aColorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
000060659 260__ $$c2017
000060659 5060_ $$aAccess copy available to the general public$$fUnrestricted
000060659 5203_ $$aColorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death. Most cases of CRC are detected in Western countries, with its incidence increasing year by year. The probability of suffering from colorectal cancer is about 4%–5% and the risk for developing CRC is associated with personal features or habits such as age, chronic disease history and lifestyle. In this context, the gut microbiota has a relevant role, and dysbiosis situations can induce colonic carcinogenesis through a chronic inflammation mechanism. Some of the bacteria responsible for this multiphase process include Fusobacterium spp, Bacteroides fragilis and enteropathogenic Escherichia coli. CRC is caused by mutations that target oncogenes, tumour suppressor genes and genes related to DNA repair mechanisms. Depending on the origin of the mutation, colorectal carcinomas can be classified as sporadic (70%); inherited (5%) and familial (25%). The pathogenic mechanisms leading to this situation can be included in three types, namely chromosomal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype (CIMP). Within these types of CRC, common mutations, chromosomal changes and translocations have been reported to affect important pathways (WNT, MAPK/PI3K, TGF-ß, TP53), and mutations; in particular, genes such as c-MYC, KRAS, BRAF, PIK3CA, PTEN, SMAD2 and SMAD4 can be used as predictive markers for patient outcome. In addition to gene mutations, alterations in ncRNAs, such as lncRNA or miRNA, can also contribute to different steps of the carcinogenesis process and have a predictive value when used as biomarkers. In consequence, different panels of genes and mRNA are being developed to improve prognosis and treatment selection. The choice of first-line treatment in CRC follows a multimodal approach based on tumour-related characteristics and usually comprises surgical resection followed by chemotherapy combined with monoclonal antibodies or proteins against vascular endothelial growth factor (VEGF) and epidermal growth receptor (EGFR). Besides traditional chemotherapy, alternative therapies (such as agarose tumour macrobeads, anti-inflammatory drugs, probiotics, and gold-based drugs) are currently being studied to increase treatment effectiveness and reduce side effects.
000060659 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/SAF2013-41651-R$$9info:eu-repo/grantAgreement/ES/ISCIII/CB06-03-1012$$9info:eu-repo/grantAgreement/ES/DGA/A32
000060659 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000060659 590__ $$a3.687$$b2017
000060659 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b52 / 171 = 0.304$$c2017$$dQ2$$eT1
000060659 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b90 / 292 = 0.308$$c2017$$dQ2$$eT1
000060659 592__ $$a1.26$$b2017
000060659 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000060659 593__ $$aPhysical and Theoretical Chemistry$$c2017$$dQ1
000060659 593__ $$aComputer Science Applications$$c2017$$dQ1
000060659 593__ $$aInorganic Chemistry$$c2017$$dQ1
000060659 593__ $$aSpectroscopy$$c2017$$dQ1
000060659 593__ $$aOrganic Chemistry$$c2017$$dQ1
000060659 593__ $$aMolecular Biology$$c2017$$dQ2
000060659 593__ $$aCatalysis$$c2017$$dQ2
000060659 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000060659 700__ $$aSánchez-de-Diego, Cristina
000060659 700__ $$aPradilla Dieste, Alberto
000060659 700__ $$0(orcid)0000-0003-2457-3674$$aCerrada, Elena$$uUniversidad de Zaragoza
000060659 700__ $$0(orcid)0000-0002-3595-7668$$aRodriguez Yoldi, María Jesús$$uUniversidad de Zaragoza
000060659 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000060659 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000060659 773__ $$g18, 1 (2017), [39 pp.]$$pInt. j. mol. sci.$$tInternational Journal of Molecular Sciences$$x1661-6596
000060659 8564_ $$s1422949$$uhttps://zaguan.unizar.es/record/60659/files/texto_completo.pdf$$yVersión publicada
000060659 8564_ $$s111855$$uhttps://zaguan.unizar.es/record/60659/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000060659 909CO $$ooai:zaguan.unizar.es:60659$$particulos$$pdriver
000060659 951__ $$a2021-03-03-16:11:10
000060659 980__ $$aARTICLE